The past, present and future of anticholinergic drugs

被引:3
作者
Healy, David [1 ]
机构
[1] Data Based Med Amer Ltd, 95 Sandringham Dr, Toronto, ON M3H 1E1, Canada
关键词
anticholinergic drugs; cognitive burden; confusion; deliriants; deprescribing; peripheral neuropathy; TRIALS COMPARING ANTIDEPRESSANTS; BURDEN INDEX; METAANALYSIS; SYMPTOMS; CLOMIPRAMINE; MEDICATIONS; CITALOPRAM; DISEASE; SYSTEM;
D O I
10.1177/20451253231176375
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In current medical practice, it is difficult to find any reports claiming that drugs that are primarily anticholinergic or those that have significant anticholinergic effects have any therapeutic benefits. These drugs fell into disrepute within the mental health field from the mid-1960s onwards, and their supposed problems extended to elsewhere in medicine after that. There is considerable evidence that this disrepute stemmed more from marketing copy rather than from hard clinical trial data. Many apparent reviews appear to repeat prior claims rather than present substantial or new evidence. This article offers a perspective rather than a systematic review as there is little evidence other than claims to review. The aim is to challenge the conventional narrative that anticholinergic effects are uniquely hazardous by pointing to the uncertain basis for claims about the harms of anticholinergic drugs, antimuscarinic drugs in particular, ending with pointers to recent research that, if realized, might underpin important possible future benefits.
引用
收藏
页数:9
相关论文
共 68 条
[1]   Deprescribing anticholinergic and sedative medicines: protocol for a Feasibility Trial (DEFEAT-polypharmacy) in residential aged care facilities [J].
Ailabouni, Nagham ;
Mangin, Dee ;
Nishtala, Prasad S. .
BMJ OPEN, 2017, 7 (04)
[2]  
Andersen B, 1990, J AFFECT DISORDERS, V18, P289
[3]   Is the chemical imbalance an 'urban legend'? An exploration of the status of the serotonin theory of depression in the scientific literature [J].
Ang, Benjamin ;
Horowitz, Mark ;
Moncrieff, Joanna .
SSM-MENTAL HEALTH, 2022, 2
[4]  
Beder D., 2021, BMJ, V375
[5]  
BEERS MH, 1991, ARCH INTERN MED, V151, P1825
[6]   Neuroleptic Malignant Syndrome: A Review for Neurohospitalists [J].
Berman, Brian D. .
NEUROHOSPITALIST, 2011, 1 (01) :41-47
[7]   Selective antagonism of muscarinic receptors is neuroprotective in peripheral neuropathy [J].
Calcutt, Nigel A. ;
Smith, Darrell R. ;
Frizzi, Katie ;
Sabbir, Mohammad Golam ;
Chowdhury, Subir K. Roy ;
Mixcoatl-Zecuatl, Teresa ;
Saleh, Ali ;
Muttalib, Nabeel ;
Van der Ploeg, Randy ;
Ochoa, Joseline ;
Gopaul, Allison ;
Tessler, Lori ;
Wess, Juergen ;
Jolivalt, Corinne G. ;
Fernyhough, Paul .
JOURNAL OF CLINICAL INVESTIGATION, 2017, 127 (02) :608-622
[8]   Oxybutynin for the Treatment of Primary Hyperhidrosis: Current State of the Art [J].
Campanati, Anna ;
Gregoriou, Stamatis ;
Kontochristopoulos, George ;
Offidani, Annamaria .
SKIN APPENDAGE DISORDERS, 2015, 1 (01) :6-13
[9]  
Carlsson A., 1996, PSYCHOPHARMACOLOGIST, P51
[10]   PIRENZEPINE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES AND THERAPEUTIC EFFICACY IN PEPTIC-ULCER DISEASE AND OTHER ALLIED DISEASES [J].
CARMINE, AA ;
BROGDEN, RN .
DRUGS, 1985, 30 (02) :85-126